Currax Pharmaceuticals LLC, of Morristown, N.J., acquired San Diego-based Nalpropion Pharmaceuticals Inc., giving Currax worldwide rights to Contrave (naltrexone HCl and bupropion HCl extended release), a prescription weight loss medicine. Currax anticipates revenues of more than $100 million from Contrave.
Emergent BioSolutions Inc., of Gaithersburg, Md., received a two-year research grant for $6.3 million from the NIH's National Institute on Drug Abuse to continue developing AP-007 for treating opioid use disorder. AP-007 is an extended-release nalmefene formulation, an opioid receptor antagonist. The research is for pre-IND, nonclinical studies. Upon completion of milestones, the project may transition to a second phase for three years of additional funding. The NIH also awarded a similar grant to Indivior plc, of Richmond, Va., to study C4X-3256, a non-opioid, highly selective orexin-1 receptor antagonist for treating opioid use disorder. Indivior plans to use the grant to take C4X-3256 from preclinical status through phase I, and perform toxicology and drug metabolism studies for a phase II study. These are two of the 375 grants awarded by the NIH this year that focus on the opioid crisis.
Relmada Therapeutics Inc., of New York, said its board approved a 1-for-4 reverse stock split in preparation for its proposed listing of its common stock on Nasdaq.
Sareum Holdings plc, of Cambridge, U.K., said it will present preclinical data next month showing that its TYK2/JAK1 inhibitor, SDC-1802, significantly reduces tumor growth in disease models of several cancers, including those of the pancreas, colon, skin and kidney, plus B-cell lymphoma.
Simcere Pharmaceutical Group, of Nanjing, China, and JW Pharmaceutical Corp., of Seoul, South Korea, signed a collaboration and exclusive license agreement to gout drug candidate URC-102 in China, including Chinese Hong Kong and Macao. Under the terms, Simcere will be responsible for the clinical research, registration and commercialization of URC-102 in China. JW will receive an up-front payment, milestones and sales royalties. Specific terms were not disclosed.
Takeda Pharmaceutical Co. Ltd., of Tokyo, will use Boston-based Cerveau Technologies Inc.'s MK-6240, an investigational imaging agent, in PET scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer's disease.